Roche (RHHBY.US) received approval for the subcutaneous injection formulation of the monoclonal antibody moketuzumab for market launch.

According to the WiseFinance APP, on November 19th, Roche (RHHBY.US) announced that the conditional marketing authorization application for Lunsumio (mosunetuzumab, moxetumomab) subcutaneous injection (SC) formulation has been approved by the European Commission (EC) for the treatment of relapsed or refractory (R/R) follicular lymphoma (FL) adult patients who have received second-line or higher systemic therapy.